Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
DPP4 inhibition impairs senohemostasis to improve plaque stability in atherosclerotic mice
Allison B. Herman, … , Edward G. Lakatta, Myriam Gorospe
Allison B. Herman, … , Edward G. Lakatta, Myriam Gorospe
Published April 25, 2023
Citation Information: J Clin Invest. 2023;133(12):e165933. https://doi.org/10.1172/JCI165933.
View: Text | PDF
Research Article Aging Vascular biology

DPP4 inhibition impairs senohemostasis to improve plaque stability in atherosclerotic mice

  • Text
  • PDF
Abstract

Senescent vascular smooth muscle cells (VSMCs) accumulate in the vasculature with age and tissue damage and secrete factors that promote atherosclerotic plaque vulnerability and disease. Here, we report increased levels and activity of dipeptidyl peptidase 4 (DPP4), a serine protease, in senescent VSMCs. Analysis of the conditioned media from senescent VSMCs revealed a unique senescence-associated secretory phenotype (SASP) signature comprising many complement and coagulation factors; silencing or inhibiting DPP4 reduced these factors and increased cell death. Serum samples from persons with high risk for cardiovascular disease contained high levels of DPP4-regulated complement and coagulation factors. Importantly, DPP4 inhibition reduced senescent cell burden and coagulation and improved plaque stability, while single-cell resolution of senescent VSMCs reflected the senomorphic and senolytic effects of DPP4 inhibition in murine atherosclerosis. We propose that DPP4-regulated factors could be exploited therapeutically to reduce senescent cell function, reverse senohemostasis, and improve vascular disease.

Authors

Allison B. Herman, Dimitrios Tsitsipatis, Carlos Anerillas, Krystyna Mazan-Mamczarz, Angelica E. Carr, Jordan M. Gregg, Mingyi Wang, Jing Zhang, Marc Michel, Charnae’ A. Henry-Smith, Sophia C. Harris, Rachel Munk, Jennifer L. Martindale, Yulan Piao, Jinshui Fan, Julie A. Mattison, Supriyo De, Kotb Abdelmohsen, Robert W. Maul, Toshiko Tanaka, Ann Zenobia Moore, Megan E. DeMouth, Simone Sidoli, Luigi Ferrucci, Yie Liu, Rafael de Cabo, Edward G. Lakatta, Myriam Gorospe

×

Figure 3

Loss or inhibition of DPP4 reduces cell-survival proteins BCL2L1 and BCL2L2.

Options: View larger image (or click on image) Download as PowerPoint
Loss or inhibition of DPP4 reduces cell-survival proteins BCL2L1 and BCL...
(A) RT-qPCR analysis of RNA from hVSMCs transfected with siCtrl or siDPP4 and treated with DMSO, CoCl2, or Doxo for 7 days. Graphs indicate the levels of DPP4, p21, LMNB1, BCL2L1, and BLC2L2 mRNAs in each group, normalized to ACTB mRNA levels. (B) RT-qPCR analysis of RNA from hVSMCs transfected with siCtrl or siDPP4 and treated with DMSO, CoCl2, or Doxo for 7 days. The levels of DPP4, p21, LMNB1, BCL2L1, and BLC2L2 mRNAs were normalized to ACTB mRNA levels. (C) Western blot analysis of protein levels of p21, LMNB1, BCL2L1, BCL2L2, and loading control ACTB in hVSMCs processed as described in A. (D) Western blot analysis of the levels of p21, LMNB1, BCL2L1, BCL2L2, and loading control ACTB in hVSMCs treated as described in B. Data are represented as mean ± SD from n = 3 or indicated biological replicates. Significance was established using Student’s t test with Bonferroni’s correction. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts